FPN || Across Specialties

Groups launch CRC screening campaign as incidence declines

Posted on: 18/03/2014 - 13:20

WASHINGTON – Several dozen organizations have joined together to help increase colorectal cancer screening rates to 80% of all Americans by 2018, citing the success of campaigns over the past decade...

Field of Interest: Oncology
Type: News Item

VIDEO: Photodynamic therapy pearls can improve results

Posted on: 14/03/2014 - 15:40

CHAMPIONSGATE, FLA. – Do you use photodynamic therapy to treat actinic keratoses? Dr. Joel Cohen has some tips for you. At the Orlando Dermatology Aesthetic and Clinical Conference, <link...

Field of Interest: Dermatology
Type: News Item

VIDEO: Allergy myths misdirect patients, physicians

Posted on: 14/03/2014 - 15:10

SAN DIEGO – Is there really such a thing as a hypoallergenic dog? (Bo Obama, we’re looking at you.) Can blood tests for sale on the Internet identify a child’s allergies? And must parents wait until...

Field of Interest: Rheumatology
Type: News Item

VIDEO: Allergy myths misdirect patients, physicians

Posted on: 14/03/2014 - 15:10

SAN DIEGO – Is there really such a thing as a hypoallergenic dog? (Bo Obama, we’re looking at you.) Can blood tests for sale on the Internet identify a child’s allergies? And must parents wait until...

Field of Interest: Gastroentero...
Type: News Item

VIDEO: Allergy myths misdirect patients, physicians

Posted on: 14/03/2014 - 15:10

SAN DIEGO – Is there really such a thing as a hypoallergenic dog? (Bo Obama, we’re looking at you.) Can blood tests for sale on the Internet identify a child’s allergies? And must parents wait until...

Field of Interest: Dermatology
Type: News Item

VIDEO: Sun protection myths debunked

Posted on: 13/03/2014 - 17:20

CHAMPIONSGATE, FLA. – Can you separate sun protection myths from facts for your patients? Misperceptions persist, but sunscreen remains a safe and effective tool to help protect the skin from...

Field of Interest: Dermatology
Type: News Item

Nivolumab extends survival in advanced melanoma

Posted on: 12/03/2014 - 14:15

An immunomodulator that targets the PD-1 pathway effected sustained remission in 31% of patients who took it for advanced melanoma. Remission lasted a median of 2 years, with 1- and 2-year overall...

Field of Interest: Oncology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness